Member Board of Directors @ (January 2023 - Present)
Scientific and Technical Advisor, SAB Chair @ (March 2024 - April 2025)
Chief Technology Officer @ (April 2021 - March 2023)
Consulting for gene and cell therapy startups - non-viral vectors and engineered cell products @ Freelance (October 2020 - April 2021)
VP, Technical Development and Manufacturing @ (May 2019 - October 2020)
VP Technical Development and Manufacturing @ Editas Medicine (September 2016 - July 2018)
Novartis, Executive Director Cell and Gene Therapies @ (August 2008 - August 2016)
Director Protein Expression and Purification Research @ Shire Human Genetic Therapies (May 2007 - August 2008)
Sr. Director Molecular Biology and Gene Expression @ Antigenics (January 2001 - January 2006)
Director Molecular Immunology @ Aquila Biopharmaceuticals (January 1998 - January 2001)
Principle Investigator II @ Procept Inc., Vactex, Inc. (January 1994 - January 1998)
Assistant Professor of Medicine @ Beth Israel Hospital and Harvard Medical School (January 1991 - January 1994)
Cancer Research Institute Postdoc, MIT Cancer Center, Sharp Lab @ (January 1988 - January 1991)
Ken Leclair Education
Massachusetts Institute of Technology
Postdoc
1988-1991
Yale University
Ph.D. (Immunobiology)
1981-1987
Bowdoin College
A.B. (Biology)
1973-1977
Ken Leclair Skills
Cell Therapy
Gene Therapy
Genome Analysis
Genome Sequencing
Immunology
Life Sciences
Molecular Biology
Protein Expression
Vaccines
Medicine
Technology
Ken Leclair Summary
Ken Leclair, based in Wellesley, MA, US, is currently a Cell and Gene Therapy Technical Advisor, Board Memberships at Freelance. Ken Leclair brings experience from previous roles at JURA Bio, Inc., RoslinCT and Freelance. Ken Leclair holds a 1988 - 1991 Postdoc @ Massachusetts Institute of Technology. With a robust skill set that includes Cell Therapy, Gene Therapy, Genome Analysis, Genome Sequencing, Immunology and more. Ken Leclair has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Ken Leclair?
Find contact details for 700 million professionals.